The SARS-CoV-2 Vaccine Pipeline: an Overview
Identifieur interne : 000155 ( 2020/Analysis ); précédent : 000154; suivant : 000156The SARS-CoV-2 Vaccine Pipeline: an Overview
Auteurs : Wen-Hsiang Chen ; Ulrich Strych ; Peter J. Hotez ; Maria Elena BottazziSource :
- Current Tropical Medicine Reports [ 2196-3045 ] ; 2020.
Abstract
The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).
Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines.
Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time.
Url:
DOI: 10.1007/s40475-020-00201-6
PubMed: 32219057
PubMed Central: 7094941
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000528
- to stream Pmc, to step Curation: 000528
- to stream Pmc, to step Checkpoint: 000042
- to stream PubMed, to step Corpus: 000496
- to stream PubMed, to step Curation: 000496
- to stream PubMed, to step Checkpoint: 000128
- to stream Ncbi, to step Merge: 003571
- to stream Ncbi, to step Curation: 003571
- to stream Ncbi, to step Checkpoint: 003571
- to stream Main, to step Merge: 000155
- to stream Main, to step Curation: 000155
- to stream Main, to step Exploration: 000155
- to stream 2020, to step Extraction: 000155
Links to Exploration step
PMC:7094941Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The SARS-CoV-2 Vaccine Pipeline: an Overview</title>
<author><name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Strych, Ulrich" sort="Strych, Ulrich" uniqKey="Strych U" first="Ulrich" last="Strych">Ulrich Strych</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32219057</idno>
<idno type="pmc">7094941</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094941</idno>
<idno type="RBID">PMC:7094941</idno>
<idno type="doi">10.1007/s40475-020-00201-6</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000528</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000528</idno>
<idno type="wicri:Area/Pmc/Curation">000528</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000528</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000042</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000042</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:32219057</idno>
<idno type="wicri:Area/PubMed/Corpus">000496</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000496</idno>
<idno type="wicri:Area/PubMed/Curation">000496</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000496</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000128</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000128</idno>
<idno type="wicri:Area/Ncbi/Merge">003571</idno>
<idno type="wicri:Area/Ncbi/Curation">003571</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003571</idno>
<idno type="wicri:Area/Main/Merge">000155</idno>
<idno type="wicri:Area/Main/Curation">000155</idno>
<idno type="wicri:Area/Main/Exploration">000155</idno>
<idno type="wicri:Area/2020/Extraction">000155</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The SARS-CoV-2 Vaccine Pipeline: an Overview</title>
<author><name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Strych, Ulrich" sort="Strych, Ulrich" uniqKey="Strych U" first="Ulrich" last="Strych">Ulrich Strych</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<affiliation><nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Current Tropical Medicine Reports</title>
<idno type="eISSN">2196-3045</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Purpose of Review</title>
<p id="Par1">The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).</p>
</sec>
<sec><title>Recent Findings</title>
<p id="Par2">Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines.</p>
</sec>
<sec><title>Summary</title>
<p id="Par3">Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl></listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<name sortKey="Strych, Ulrich" sort="Strych, Ulrich" uniqKey="Strych U" first="Ulrich" last="Strych">Ulrich Strych</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000155 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000155 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= 2020 |étape= Analysis |type= RBID |clé= PMC:7094941 |texte= The SARS-CoV-2 Vaccine Pipeline: an Overview }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32219057" \ | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |